{"id":"tritanrix-hepb-meningitec-conjugate-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine contains inactivated or killed pathogens and antigens from the listed diseases. Upon administration, the antigens are recognized by the immune system, triggering a response that produces antibodies to neutralize or remove the pathogens. This provides long-term immunity against the diseases.","oneSentence":"Tritanrix-HepB/Meningitec conjugate vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:08.985Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Protection against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y in infants and young children"}]},"trialDetails":[{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00317135","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-11","conditions":"Diphtheria, Hepatitis B, Whole Cell Pertussis","enrollment":500},{"nctId":"NCT00317187","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-08","conditions":"Hepatitis B, Diphtheria, Whole Cell Pertussis","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DTPw-HBV/Hib-MenAc conjugate vaccine","DTPw-HBV/Hib-MenAC conjugate vaccine"],"phase":"phase_3","status":"active","brandName":"Tritanrix-HepB/Meningitec conjugate vaccine","genericName":"Tritanrix-HepB/Meningitec conjugate vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tritanrix-HepB/Meningitec conjugate vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y in infants and young children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}